Struggling to get tough biotech patents allowed? A reactive, traditional "strategy" often fails. Try these 4 proactive, effective...

(Check out the short version of this post, if you don't want all the details in this patent professional version.) Introduction: It can...

SUMMARY   In this post we present a prioritization matrix tool that enables your IP team to dedicate an appropriate amount of resources...

Biotech products and processes evolve over time. This can cause a misalignment between your issued/pending patent claims, and your...

Biotech innovation is regularly faced with a thicket of prior art that applicants must navigate during patent prosecution. Examiners at...

This week, we’re celebrating a decade of helping life sciences innovators protect their groundbreaking IP. We are grateful for every...

SUMMARY: Biologic candidates evolve during clinical trials - so should your patents. Updated filings before public trial disclosures...

Too many biotech companies treat IP like a checkbox. Smart ones prune ruthlessly—and build value, not just volume: Prune entire families...

INTRODUCTION Executives usually ask these quantitative but high-level questions: How much money did we spend on patent work this year?...

As a biotech company, much of your value is in (pre-revenue) and/or protected by (post-revenue) your intellectual property. As you...

Working examples are an important part of a biotech patent application, especially because this is considered an unpredictable art in...

SUMMARY Costs for prosecuting patents at the USPTO are set to increase on 1/19/25 Across-the-board 7.5% increase in fees Some targeted...

Like many technology areas, the vast majority of, if not all, biotech/biopharma inventions build on prior art teachings. Thus, a major...

The USPTO has provided 49 examples* to help understand the application of Section 101 (35 U.S.C. 101), subject matter eligibility, in...

Common misconceptions about patent rights: In my decades of counseling life sciences companies, I have found that many inventors and...

When should we assure we have FTO for our private biotech company? Summary: FTO for a private biotech company is typically a multi-stage...

101 rejections at the USPTO plummeted in computational biology in 2023!      We analyzed office actions since 2008 related to...

INTRODUCTORY COMMENTS RE: BIOTECH/PHARMA EXTENDED PATENT FAMILIES In complex art areas like biotech/biopharma, patent strategy is about...

It's that time of year again... Annual patent planning for your company/client(s) for next year. Here are some key dates to track as you...

A day to celebrate biotech! 🥳 Congrats to Vertex and CRISPR Therapeutics on FDA approval of CASGEVY • 1st product that uses gene editing...